APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points

Jon B. Toledo, Mohamad Habes, Aristeidis Sotiras, Maria Bjerke, Yong Fan, Michael W. Weiner, Leslie M. Shaw, Christos Davatzikos, John Q. Trojanowski

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


There are conflicting results regarding how APOE genotype, the strongest genetic risk factor for Alzheimer's disease (AD), influences spatial and longitudinal amyloid-β (Aβ) deposition and its impact on the selection of biomarker cut-points. In our study, we sought to determine the impact of APOE genotype on cross-sectional and longitudinal florbetapir positron emission tomography (PET) amyloid measures and its impact in classification of patients and interpretation of clinical cohort results. We included 1,019 and 1,072 Alzheimer's Disease Neuroimaging Initiative participants with cerebrospinal fluid Aβ 1 - 42 and florbetapir PET values, respectively. 623 of these subjects had a second florbetapir PET scans two years after the baseline visit. We evaluated the effect of APOE genotype on Aβ distribution pattern, pathological biomarker cut-points, cross-sectional clinical associations with Aβ load, and longitudinal Aβ deposition rate measured using florbetapir PET scans. 1) APOE ϵ4 genotype influences brain amyloid deposition pattern; 2) APOE ϵ4 genotype does not modify Aβ biomarker cut-points estimated using unsupervised mixture modeling methods if white matter and brainstem references are used (but not when cerebellum is used as a reference); 3) findings of large differences in Aβ biomarker value differences based on APOE genotype are due to increased probability of having AD neuropathology and are most significant in mild cognitive impairment subjects; and 4) APOE genotype and age (but not gender) were associated with increased Aβ deposition rate. APOE ϵ4 carrier status affects rate and location of brain Aβ deposition but does not affect choice of biomarker cut-points if adequate references are selected for florbetapir PET processing.

Original languageEnglish (US)
Pages (from-to)783-793
Number of pages11
JournalJournal of Alzheimer's Disease
Issue number3
StatePublished - 2019
Externally publishedYes


  • Alzheimer's disease
  • amyloid-β
  • cerebrospinal fluid
  • diagnosis
  • mild cognitive impairment
  • positron emission tomography

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Clinical Psychology
  • General Neuroscience


Dive into the research topics of 'APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points'. Together they form a unique fingerprint.

Cite this